Opportunities to Get Involved

From time-to-time, the PGRN and PharmGKB offer opportunities to the scientific public to get involved.

Current Opportunities:

• FDA Criteria for Consideration of Potential Candidates for Drug Relabeling with Pharmacogenomic Information

Requests for information related to pharmacogenomics:

• DRAFT guidance from FDA on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies (comment by April 15, 2011)

NIH Statements on Pharmacogenomics and Genomic Medicine:

• Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
  Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM.
  J Natl Cancer Inst. 2010 Nov 17;102(22):1698-705. Epub 2010 Oct 13.
  PMID: 20944079

• Charting a course for genomic medicine from base pairs to bedside.
  Green ED, Guyer MS; National Human Genome Research Institute.
  Nature. 2011 Feb 10;470(7333):204-13.
  PMID: 21307933